Evidence map›Paper›PMID 27446412›Full record

ArticleOncology letters2016

FOXL2 molecular status in adult granulosa cell tumors of the ovary: A study of primary and metastatic cases.

Gian Franco Zannoni, Giuseppina Improta, Marco Petrillo, Angela Pettinato, Giovanni Scambia, Filippo Fraggetta

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  3. FOXO1 mitigates the SMAD3/FOXL2Journal of translational medicine · 2021
    Article
  4. FOXO1 Negates the Cooperative Action of FOXL2Journal of the Endocrine Society · 2019
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gian Franco ZannoniDepartment of Pathology, Catholic University of The Sacred Heart, I-00168 Rome, Italy.
Giuseppina ImprotaLaboratory of Clinical Research and Advanced Diagnostics, Hospitalization and Treatment Institute Scientific-Oncological Referral Center of Basilicata, I-85028 Potenza, Italy.
Marco PetrilloDepartment of Obstetrics and Gynecology, Catholic University of the Sacred Heart, I-00168 Rome, Italy.
Angela PettinatoDepartment of Pathology, Cannizzaro Hospital, I-95126 Catania, Italy.
Giovanni ScambiaDepartment of Obstetrics and Gynecology, Catholic University of the Sacred Heart, I-00168 Rome, Italy.
Filippo FraggettaDepartment of Pathology, Cannizzaro Hospital, I-95126 Catania, Italy.
Università Cattolica del Sacro Cuore · ITOspedale Cannizzaro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulosa cell tumors (GCTs) of the ovary are uncommon neoplasms, accounting for ~5% of all malignant ovarian tumors. GCTs are a relatively homogeneous group of tumors, categorized into two distinct subtypes, juvenile GCT and adult GCT (AGCT), likely arising from a limited set of molecular events usually involving the disruption of pathways that regulate granulosa cell proliferation. In the present study, the presence of forkheadbox L2 (FOXL2) c.402C>G mutation was investigated in a series of 42 samples of primary and metastatic AGCT of the ovary. The samples consisted of 37 primary and 5 metastatic ovarian AGCTs from 37 patients. FOXL2 mutational status was evaluated using a pyrosequencing approach on 2.5-µm sections of formalin-fixed paraffin-embedded tissue. FOXL2 c.402C>G mutation was found in 33/37 (89.2%) primary AGCTs and in 4/5 (80.0%) metastases, with the molecular status of the metastases recapitulating that of the primary tumors (4 mutated cases and 1 wild-type case). Overall, FOXL2 mutation is present in the majority of primary and metastatic AGCTs, and could be used as a valid tool in the diagnosis of the disease and in cases of metastatic lesions from an unknown primary origin. Moreover the concordance of FOXL2 molecular status in primary and associated metastases suggests its early appearance and genomic stability in AGCT tumorigenesis.

Indexed as

FOXL2granulosa cell tumorsmolecular signaturesmutationovary

Identifiers

PMID27446412
PMCPMC4950087
OpenAlexW2420953416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.